Efficacy and Rebound Effects of Repeated Low-Level Red Light versus High-Concentration Atropine for Myopia Control in Children: A Randomized Controlled Trial.

Λεπτομέρειες βιβλιογραφικής εγγραφής
Τίτλος:	Efficacy and Rebound Effects of Repeated Low-Level Red Light versus High-Concentration Atropine for Myopia Control in Children: A Randomized Controlled Trial.
Συγγραφείς:	Xie J; Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.; National Clinical Research Center for Eye Diseases, Shanghai, China.; Shanghai Key Laboratory of Ocular Fundus Diseases, Shanghai, China.; Shanghai Engineering Center for Visual Science and Photomedicine, Shanghai, China.; Shanghai Engineering Center for Precise Diagnosis and Treatment of Eye Diseases, Shanghai, China., Zhang Z; Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.; National Clinical Research Center for Eye Diseases, Shanghai, China.; Shanghai Key Laboratory of Ocular Fundus Diseases, Shanghai, China.; Shanghai Engineering Center for Visual Science and Photomedicine, Shanghai, China.; Shanghai Engineering Center for Precise Diagnosis and Treatment of Eye Diseases, Shanghai, China., Zhang T; Penn Medicine Doylestown Health, Doylestown, Pennsylvania, USA., Xie D; Department of Biostatistics, Epidemiology, and Informatics, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA., Xu X; Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.; National Clinical Research Center for Eye Diseases, Shanghai, China.; Shanghai Key Laboratory of Ocular Fundus Diseases, Shanghai, China.; Shanghai Engineering Center for Visual Science and Photomedicine, Shanghai, China.; Shanghai Engineering Center for Precise Diagnosis and Treatment of Eye Diseases, Shanghai, China., Lu Y; Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.; National Clinical Research Center for Eye Diseases, Shanghai, China.; Shanghai Key Laboratory of Ocular Fundus Diseases, Shanghai, China.; Shanghai Engineering Center for Visual Science and Photomedicine, Shanghai, China.; Shanghai Engineering Center for Precise Diagnosis and Treatment of Eye Diseases, Shanghai, China.
Πηγή:	Clinical & experimental ophthalmology [Clin Exp Ophthalmol] 2026 Jul; Vol. 54 (5), pp. 605-616. Date of Electronic Publication: 2026 Mar 08.
Τύπος έκδοσης:	Journal Article; Randomized Controlled Trial; Comparative Study
Γλώσσα:	English
Στοιχεία περιοδικού:	Publisher: Wiley-Blackwell Pub. Asia Country of Publication: Australia NLM ID: 100896531 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1442-9071 (Electronic) Linking ISSN: 14426404 NLM ISO Abbreviation: Clin Exp Ophthalmol Subsets: MEDLINE
Imprint Name(s):	Publication: Carlton, Vic. : Wiley-Blackwell Pub. Asia Original Publication: Carlton, Vic. : Blackwell Science Asia, c2000-
Ιατρικοί όροι (MeSH):	Myopia/physiopathology , Myopia/therapy , Myopia/drug therapy , Myopia/diagnosis , Atropine/administration & dosage , Mydriatics/administration & dosage , Red Light*, Refraction, Ocular/physiology ; Visual Acuity/physiology ; Humans ; Child ; Prospective Studies ; Female ; Single-Blind Method ; Axial Length, Eye ; Male ; Treatment Outcome ; Follow-Up Studies ; Tomography, Optical Coherence ; Ophthalmic Solutions
Περίληψη:	Background: To compare the efficacy of repeated low-level red light (RLRL) and high-concentration atropine (HCA, 1%) in myopia control and evaluate rebound effects after cessation. Methods: In this 15-month, prospective, single-blinded randomized controlled trial, 136 myopic children (6-12 years) were randomly assigned to RLRL or HCA (1:1). Treatment lasted 12 months followed by a 3-month washout. Outcomes included change in axial length (AL), spherical equivalent refraction (SER), subfoveal choroidal thickness (SFChT), and safety. Results: A total of 116 children completed ≥ 1 follow-up (RLRL: 65, HCA: 51). At 12 months, RLRL showed superior efficacy: AL regressed by -0.014 mm (95% CI: -0.067 to 0.039) versus a 0.094 mm increase with HCA (95% CI: 0.046-0.141; p = 0.005). SER decreased by 0.24 D (95% CI: 0.093-0.387) in RLRL and increased by 0.035 D (95% CI: -0.154 to 0.083) in HCA (p = 0.008), while SFChT increased by 26.000 μm (95% CI: 18.082-33.918) and 12.761 μm (95% CI: 3.867-21.655; p = 0.032), respectively. During the 3-month washout, AL elongation was slightly greater in RLRL (0.163 mm) compared to HCA (0.115 mm; p = 0.014). Higher compliance (≥ 75%) with RLRL correlated with better 12-month efficacy (AL: -0.064 mm vs. 0.084 mm; p = 0.011) but worse rebound (AL: 0.183 mm vs. 0.122 mm; p = 0.02). No severe adverse events were reported. Conclusions: RLRL exhibited superior 12-month efficacy over HCA (1%) but was associated with slightly higher rebound. Optimizing RLRL regimens, including implementing reduced dosing and tapered withdrawal, could sustain benefits while limiting rebound. Trial Registration: Chinese Clinical Trial Registry: ChiCTR2100051940. (© 2026 Royal Australian and New Zealand College of Ophthalmologists.)
References:	I. G. Morgan, A. N. French, R. S. Ashby, et al., “The epidemics of myopia: Aetiology and prevention,” Progress in Retinal and Eye Research 62 (2018): 134–149. K. Ohno‐Matsui, P. C. Wu, K. Yamashiro, et al., “IMI Pathologic Myopia,” Investigative Ophthalmology & Visual Science 62, no. 5 (2021): 5. J. B. Jonas, M. Ang, P. Cho, et al., “IMI Prevention of Myopia and Its Progression,” Investigative Ophthalmology & Visual Science 62, no. 5 (2021): 6. J. Huang, D. Wen, Q. Wang, et al., “Efficacy Comparison of 16 Interventions for Myopia Control in Children: A Network Meta‐analysis,” Ophthalmology 123, no. 4 (2016): 697–708. A. Chia, W. H. Chua, Y. B. Cheung, et al., “Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2),” Ophthalmology 119, no. 2 (2012): 347–354. A. Chia, W. H. Chua, L. Wen, A. Fong, Y. Y. Goon, and D. Tan, “Atropine for the treatment of childhood myopia: changes after stopping atropine 0.01%, 0.1% and 0.5%,” American Journal of Ophthalmology 157, no. 2 (2014): 451–457. A. Chia, Q. S. Lu, and D. Tan, “Five‐Year Clinical Trial on Atropine for the Treatment of Myopia 2: Myopia Control with Atropine 0.01% Eyedrops,” Ophthalmology 123, no. 2 (2016): 391–399. J. C. Yam, Y. Jiang, S. M. Tang, et al., “Low‐Concentration Atropine for Myopia Progression (LAMP) Study: A Randomized, Double‐Blinded, Placebo‐Controlled Trial of 0.05%, 0.025%, and 0.01% Atropine Eye Drops in Myopia Control,” Ophthalmology 126, no. 1 (2019): 113–124. J. C. Yam, F. F. Li, X. Zhang, et al., “Two‐Year Clinical Trial of the Low‐Concentration Atropine for Myopia Progression (LAMP) Study: Phase 2 Report,” Ophthalmology 127, no. 7 (2020): 910–919. J. C. Yam, X. J. Zhang, Y. Zhang, et al., “Three‐Year Clinical Trial of Low‐Concentration Atropine for Myopia Progression (LAMP) Study: Continued Versus Washout: Phase 3 Report,” Ophthalmology 129, no. 3 (2022): 308–321. X. J. Zhang, Y. Zhang, B. H. K. Yip, et al., “Five‐Year Clinical Trial of the Low‐Concentration Atropine for Myopia Progression (LAMP) Study: Phase 4 Report,” Ophthalmology 131, no. 9 (2024): 1011–1020. W. H. Chua, V. Balakrishnan, Y. H. Chan, et al., “Atropine for the Treatment of Childhood Myopia,” Ophthalmology 113, no. 12 (2006): 2285–2291. L. Tong, X. L. Huang, A. L. Koh, X. Zhang, D. T. Tan, and W. H. Chua, “Atropine for the Treatment of Childhood Myopia: Effect on Myopia Progression After Cessation Of Atropine,” Ophthalmology 116, no. 3 (2009): 572–579. Q. Zhu, Y. Tang, L. Guo, et al., “Efficacy and Safety of 1% Atropine on Retardation of Moderate Myopia Progression in Chinese School Children,” International Journal of Medical Sciences 17, no. 2 (2020): 176–181. L. Du, L. Ding, J. Chen, et al., “Efficacy of Weekly Dose of 1% Atropine for Myopia Control in Chinese Children,” British Journal of Ophthalmology 109, no. 2 (2025): 264–272. L. L. Foo, H. Htoon, S. Z. Farooqui, and A. Chia, “Part‐Time Use of 1% Atropine Eye Drops for Prevention of Myopia Progression in Children,” International Ophthalmology 40, no. 7 (2020): 1857–1862. F. Xiong, T. Mao, H. Liao, et al., “Orthokeratology and Low‐Intensity Laser Therapy for Slowing the Progression of Myopia in Children,” BioMed Research International 2021 (2021): 8915867. Y. Chen, R. Xiong, X. Chen, et al., “Efficacy Comparison of Repeated Low‐Level Red Light and Low‐Dose Atropine for Myopia Control: A Randomized Controlled Trial,” Translational Vision Science & Technology 11, no. 10 (2022): 33. Y. Jiang, Z. Zhu, X. Tan, et al., “Effect of Repeated Low‐Level Red‐Light Therapy for Myopia Control in Children: A Multicenter Randomized Controlled Trial,” Ophthalmology 129, no. 5 (2022): 509–519. R. Xiong, Z. Zhu, Y. Jiang, et al., “Sustained and Rebound Effect of Repeated Low‐Level Red‐Light Therapy on Myopia Control: A 2‐Year Post‐Trial Follow‐Up Study,” Clinical & Experimental Ophthalmology 50, no. 9 (2022): 1013–1024. H. Chen, W. Wang, Y. Liao, et al., “Low‐Intensity Red‐Light Therapy in Slowing Myopic Progression and the Rebound Effect After its Cessation in Chinese Children: A Randomized Controlled Trial,” Graefe's Archive for Clinical and Experimental Ophthalmology 261, no. 2 (2023): 575–584. J. Dong, Z. Zhu, H. Xu, and M. He, “Myopia Control Effect of Repeated Low‐Level Red‐Light Therapy in Chinese Children: A Randomized, Double‐Blind, Controlled Clinical Trial,” Ophthalmology 130, no. 2 (2023): 198–204. G. Liu, H. Rong, Y. Liu, et al., “Effectiveness of Repeated Low‐Level Red Light in Myopia Prevention and Myopia Control,” British Journal of Ophthalmology 108, no. 9 (2024): 1299–1305. X. He, J. Wang, Z. Zhu, et al., “Effect of Repeated Low‐level Red Light on Myopia Prevention Among Children in China With Premyopia: A Randomized Clinical Trial,” JAMA Network Open 6, no. 4 (2023): e239612. L. Tian, K. Cao, D. L. Ma, et al., “Six‐Month Repeated Irradiation of 650 nm Low‐Level Red Light Reduces the Risk of Myopia in Children: A Randomized Controlled Trial,” International Ophthalmology 43, no. 10 (2023): 3549–3558. Y. Xu, L. Cui, M. Kong, et al., “Repeated Low‐Level Red Light Therapy for Myopia Control in High Myopia Children and Adolescents: A Randomized Clinical Trial,” Ophthalmology 131, no. 11 (2024): 1314–1323. R. Xiong, W. Wang, X. Tang, et al., “Myopia Control Effect of Repeated Low‐Level Red‐Light Therapy Combined with Orthokeratology: A Multicenter Randomized Controlled Trial,” Ophthalmology 131, no. 11 (2024): 1304–1313. Y. Yang, S. Liu, W. Gao, et al., “Synergistic Effect of Defocus Incorporated Multiple Segment Glasses and Repeated Low Level Red Light Therapy Against Myopia Progression,” Scientific Reports 15, no. 1 (2025): 3996. L. Ye, Y. Shi, Y. Yin, et al., “Effects of Atropine Treatment on Choroidal Thickness in Myopic Children,” Investigative Ophthalmology & Visual Science 61, no. 14 (2020): 15. W. Wang, Y. Jiang, Z. Zhu, et al., “Axial Shortening in Myopic Children after Repeated Low‐Level Red‐Light Therapy: Post Hoc Analysis of a Randomized Trial,” Ophthalmology and therapy 12, no. 2 (2023): 1223–1237. F. F. Li, K. W. Kam, Y. Zhang, et al., “Differential Effects on Ocular Biometrics by 0.05%, 0.025%, and 0.01% Atropine: Low‐Concentration Atropine for Myopia Progression Study,” Ophthalmology 127, no. 12 (2020): 1603–1611. R. Xu, P. Zhong, C. Jan, et al., “Sex Disparity in Myopia Explained by Puberty Among Chinese Adolescents From 1995 to 2014: A Nationwide Cross‐Sectional Study,” Frontiers in Public Health 10 (2022): 833960. S. S. Lee, G. Lingham, P. G. Sanfilippo, et al., “Incidence and Progression of Myopia in Early Adulthood,” JAMA Ophthalmology 140, no. 2 (2022): 162–169. S. M. Saw, W. H. Chua, G. Gazzard, D. Koh, D. T. Tan, and R. A. Stone, “Eye Growth Changes in Myopic Children in Singapore,” British Journal of Ophthalmology 89, no. 11 (2005): 1489–1494. S. Yi, Y. Huang, S. Z. Yu, X. J. Chen, H. Yi, and X. L. Zeng, “Therapeutic Effect of Atropine 1% in Children with Low Myopia,” Journal of AAPOS 19, no. 5 (2015): 426–429. K. L. Loh, Q. Lu, D. Tan, and A. Chia, “Risk Factors for Progressive Myopia in the Atropine Therapy for Myopia Study,” American Journal of Ophthalmology 159, no. 5 (2015): 945–949. X. He and X. Xu, “Expert Consensus on the Application of Axial Length in Myopia Prevention and Control Management (2023),” Chinese Journal of Experimental Ophthalmology 42, no. 1 (2024): 1–11. X. Liao, J. Yu, Y. Fan, et al., “Cone Density Changes After Repeated Low‐Level Red Light Treatment in Children With Myopia,” JAMA Ophthalmology 143, no. 6 (2025): 480–488. J. L. Duncan, “Repeated Low‐Level Red Light‐More Than Meets the Eye?,” JAMA Ophthalmology 143, no. 6 (2025): 488–489. Z. Hongmei, H. Xiangui, J. Ying, et al., “Does Repeated Low‐Level Red Light Therapy Affect Cone Density in the Macula of Myopic Children?,” Chinese Journal of Experimental Ophthalmology 43, no. 6 (2025): 496–498. J. Tang, Y. Liao, N. Yan, et al., “Efficacy of Repeated Low‐Level Red‐Light Therapy for Slowing the Progression of Childhood Myopia: A Systematic Review and Meta‐Analysis,” American Journal of Ophthalmology 252 (2023): 153–163. Z. Jiang, S. Chen, R. Wang, and J. Ma, “Safety of and Chorioretinal Circulation During Repeated Low‐Level Red‐Light Therapy for Myopic Children,” Clinical & Experimental Ophthalmology 53, no. 2 (2025): 119–132. H. Liu, Y. Yang, J. Guo, J. Peng, and P. Zhao, “Retinal Damage After Repeated Low‐level Red‐Light Laser Exposure,” JAMA Ophthalmology 141, no. 7 (2023): 693–695. X. Wang, L. Zhang, J. Gan, Y. Wang, and W. Yang, “Effectiveness of Various Atropine Concentrations in Myopia Control for Asian Children: A Network Meta‐Analysis,” Frontiers in Pharmacology 15 (2024): 1503536. P. Sankaridurg and H. D. M. Tran, “The Lowdown on Low‐Concentration Atropine for Myopia Progression,” Ophthalmology 126, no. 1 (2019): 125–126. J. Cooper, N. Eisenberg, E. Schulman, and F. M. Wang, “Maximum Atropine Dose Without Clinical Signs or Symptoms,” Optometry and Vision Science 90, no. 12 (2013): 1467–1472. Z. Zhang, L. Lv, D. Chen, F. Li, and J. Zhou, “Molecular Changes in Intraocular Fluid: Implications for Myopia,” International Journal of Biological Sciences 20, no. 13 (2024): 5330–5342. H. Wu, W. Chen, F. Zhao, et al., “Scleral Hypoxia is a Target for Myopia Control,” Proceedings of the National Academy of Sciences of the United States of America 115, no. 30 (2018): E7091–e100. C. E. Moon, Y. W. Ji, J. K. Lee, et al., “Retinal Proteome Analysis Reveals a Region‐Specific Change in the Rabbit Myopia Model,” International Journal of Molecular Sciences 24, no. 2 (2023): 1286. Q. Yu, C. Wang, Z. Liu, et al., “Association Between Inflammatory Cytokines and Oxidative Stress Levels in Aqueous Humor With Axial Length in Human Myopia,” Experimental Eye Research 237 (2023): 109670. R. Xu, J. Zheng, L. Liu, and W. Zhang, “Effects of Inflammation on Myopia: Evidence and Potential Mechanisms,” Frontiers in Immunology 14 (2023): 1260592. L. Zeng, X. Li, J. Liu, H. Liu, H. Xu, and Z. Yang, “RNA‐Seq Analysis Reveals an Essential Role of the Tyrosine Metabolic Pathway and Inflammation in Myopia‐Induced Retinal Degeneration in Guinea Pigs,” International Journal of Molecular Sciences 22, no. 22 (2021): 12598. H. Chichan, I. H. Aldujaly, K. Michalakis, and L. Kanal, “Photobiomodulation in Ocular Therapy: Current Status and Future Perspectives,” International Journal of Ophthalmology 18, no. 2 (2025): 351–357. Y. Gao, X. Zhu, Y. Luo, X. Wu, L. Tan, and H. Qiu, “Low‐Level Red Light Inhibits Human Retinal Pigment Epithelial Cell Fibrosis via UBE2C in a Myopia‐Simulating Hypoxic Microenvironment,” European Journal of Medical Research 30, no. 1 (2025): 530.
Grant Information:	82401279 National Natural Science Foundation of China
Contributed Indexing:	Keywords: axial length; high‐concentration atropine; myopic control; repeated low‐level red light; spherical equivalent refraction
Substance Nomenclature:	7C0697DR9I (Atropine) 0 (Mydriatics) 0 (Ophthalmic Solutions)
Entry Date(s):	Date Created: 20260309 Date Completed: 20260707 Latest Revision: 20260726
Update Code:	20260727
DOI:	10.1111/ceo.70101
PMID:	41796439
Βάση Δεδομένων:	MEDLINE

Περιγραφή
ISSN:	1442-9071
DOI:	10.1111/ceo.70101